Günther Weindl
Prof. Dr. Günther Weindl
Zugehörigkeiten
  • Pharmazeutisches Institut
Forschungsschwerpunkte
  • pharmacology
  • cellular signal transduction
  • inflammation
Our research in experimental pharmacology and cellular signal transduction focuses on understanding the molecular mechanisms of drugs that play an important role in inflammatory and immunological processes. In other words, we want to understand the mode of action of drugs that interact with receptors and signalling pathways to foster the development of drugs for the therapy of inflammatory diseases. Immunopharmacological concepts, and particularly the characterization of potentially novel immunomodulatory drugs, such as Toll-like receptor modulators and synthetic peptides, are at the core of our research activities. Current investigations also focus on the regulation of inflammatory responses by autophagy and the mechanisms of lysosomotropic drugs at the molecular level.
Ausgewählte Publikationen

Müller G, Lübow C, Weindl G (2019) Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells. Autophagy Nov 7:1-16 [Epub ahead of print]

Grabowski M, Murgueitio MS, Bermudez M, Wolber G, Weindl G (2020) The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2/1 signaling. Biochem Pharmacol 171:113687.

Pfalzgraff A, Bárcena-Varela S, Heinbockel L, Gutsmann T, Brandenburg K, Martinez-de-Tejada G, Weindl G (2018) Antimicrobial endotoxin-neutralizing peptides promote keratinocyte migration via P2X7 receptor activation and accelerate wound healing in vivo. Br J Pharmacol 175:3581-3593,

Su Q, Weindl G (2018) Glucocorticoids and Toll-like receptor 2 cooperatively induce acute-phase serum amyloid A. Pharmacol Res 128:145-152.

Günther Weindl
Prof. Dr. Günther Weindl
Wird geladen